Antisense Therapeutics Ltd
ASX:ANP
Antisense Therapeutics Ltd
ASX:ANP
Price:
0.084 AUD
1.2%
Market Closed
Updated:
May 4, 2024
Antisense Therapeutics Ltd
Net Income (Common)
|
Antisense Therapeutics Ltd
Net Income (Common) Peer Comparison
Comparables:
MYX
NEU
BOT
PBP
C
CU6
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Antisense Therapeutics Ltd
ASX:ANP
|
Net Income (Common)
-AU$11.4m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-17%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Net Income (Common)
AU$117.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Net Income (Common)
AU$157.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
120%
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Net Income (Common)
-AU$14.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-24%
|
|
|
Probiotec Ltd
ASX:PBP
|
Net Income (Common)
AU$8.7m
|
CAGR 3-Years
29%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
21%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Net Income (Common)
-AU$24.6m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Antisense Therapeutics Ltd's Net Income (Common)?
Net Income (Common)
-11.4m
AUD
-11.4m
AUD
Based on the financial report for Jun 30, 2023, Antisense Therapeutics Ltd's Net Income (Common) amounts to -11.4m AUD.
What is Antisense Therapeutics Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-17%
-17%
Over the last year, the Net Income (Common) growth was -96%. The average annual Net Income (Common) growth rates for Antisense Therapeutics Ltd have been -24% over the past three years , -37% over the past five years , and -17% over the past ten years .
You don't have any saved screeners yet
